Amorcyte, Inc. Opens Cell Therapy Trial for Cardiovascular Disease at Emory University; Initial Study to Focus on Safety, Efficacy, and Mechanism of Action
Posted on: Monday, 5 June 2006, 09:02 CDT
Amorcyte, Inc. (Amorcyte), a privately funded cell therapy company developing products to treat cardiovascular disease, announced today that its Phase I clinical trial is now open at Emory University School of Medicine, under Arshed A. Quyyumi, M.D., FRCP, FACC, Professor of Medicine, Cardiology, and is expected to open in another center within 90 days.
"In many ways this is an important and unique Phase I trial for the developing field of cell therapies for cardiovascular disease," states Dr. Quyyumi. "In addition to safety, this trial will assess the effect of stem cell dose on definitive clinical endpoints following administration after myocardial infarction."
"The trial end points should facilitate rapid performance of a Phase II and subsequent trials if safety and biologic activity is observed," states Dr. Thomas Moss, Amorcyte's Chief Medical Officer. "We have garnered significant support and contributions from a wide variety of cell therapy and cardiology experts who have advised us on this development strategy."
It is estimated there are approximately 1.1 million instances of acute myocardial infarction, 12 million cases of chronic ischemia, and 5 million occurrences of congestive heart failure in the United States per year. A significant percentage of these patients are in need of additional therapies to ameliorate the symptoms of their disease. Products including AMR-001 are now under active investigation to determine safety and potential biologic activity.
Amorcyte expects to enroll its first patients in June and is actively recruiting patients for the trial.
About Amorcyte, Inc.
Amorcyte, Inc. is a therapeutics company pursuing cell based therapies for cardiovascular diseases, reimbursable on a commercial scale for widespread clinical use. Amorcyte was incorporated in May 2005 and received FDA approval for its Phase I trial IND in September 2005. Watch for the launch of www.amorcyte.com coming soon.
Source: Business Wire
Related Articles
- Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
- AVEO Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of AV-951 in Patients With Metastatic Renal Cell Carcinoma
- Introgen Announces Positive Phase 2 Clinical Trial Results With INGN 225 Immunotherapy in Patients With Small Cell Lung Cancer
- Amorcyte Cardiac Cell Therapy Trial Completes Second of Four Phases
- Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating Glufosfamide in Patients With Recurrent, Sensitive Small Cell Lung Cancer
- University of Cincinnati and CardioVascular BioTherapeutics to Host Reunion Celebration for Patients Involved in Phase I Clinical Trial
- Cytokinetics Announces Positive Phase I Clinical Trial Results for CK-1827452
- Curis Provides Update on Ongoing Basal Cell Carcinoma Phase I Clinical Trial
- Covalent Group, Inc. Signs Letter-of-Intent to Conduct $2.2 Million Multinational Phase 2 Clinical Trial in Cardiovascular Disease
- NeoRx Announces Treatment of First Patient With Picoplatin in Phase 2 Clinical Trial in Small Cell Lung Cancer
 |
 |
User Comments (0)
RSS Feeds